160 related articles for article (PubMed ID: 38528310)
1. Danicopan: First Approval.
Kang C
Drugs; 2024 May; 84(5):613-618. PubMed ID: 38528310
[TBL] [Abstract][Full Text] [Related]
2. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial.
Lee JW; Griffin M; Kim JS; Lee Lee LW; Piatek C; Nishimura JI; Carrillo Infante C; Jain D; Liu P; Filippov G; Sicre de Fontbrune F; Risitano A; Kulasekararaj AG;
Lancet Haematol; 2023 Dec; 10(12):e955-e965. PubMed ID: 38030318
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab.
Kulasekararaj AG; Risitano AM; Maciejewski JP; Notaro R; Browett P; Lee JW; Huang M; Geffner M; Brodsky RA
Blood; 2021 Nov; 138(20):1928-1938. PubMed ID: 34314483
[TBL] [Abstract][Full Text] [Related]
4. Crovalimab: First Approval.
Dhillon S
Drugs; 2024 Jun; 84(6):707-716. PubMed ID: 38740735
[TBL] [Abstract][Full Text] [Related]
5. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
[TBL] [Abstract][Full Text] [Related]
6. Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria.
Heo YA
Drugs; 2022 Dec; 82(18):1727-1735. PubMed ID: 36459381
[TBL] [Abstract][Full Text] [Related]
7. Ravulizumab: First Global Approval.
McKeage K
Drugs; 2019 Feb; 79(3):347-352. PubMed ID: 30767127
[TBL] [Abstract][Full Text] [Related]
8. Iptacopan: First Approval.
Syed YY
Drugs; 2024 May; 84(5):599-606. PubMed ID: 38517653
[TBL] [Abstract][Full Text] [Related]
9. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
Front Immunol; 2019; 10():1157. PubMed ID: 31258525
[TBL] [Abstract][Full Text] [Related]
10. Pegcetacoplan: First Approval.
Hoy SM
Drugs; 2021 Aug; 81(12):1423-1430. PubMed ID: 34342834
[TBL] [Abstract][Full Text] [Related]
11. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Lee JW; Kulasekararaj AG
Expert Opin Biol Ther; 2020 Mar; 20(3):227-237. PubMed ID: 32011183
[No Abstract] [Full Text] [Related]
12. Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis.
Cheng WY; Fishman J; Yenikomshian M; Mahendran M; Kunzweiler C; Vu JD; Duh MS
Adv Ther; 2024 Jan; 41(1):413-430. PubMed ID: 37999832
[TBL] [Abstract][Full Text] [Related]
13. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
Kulasekararaj AG; Hill A; Rottinghaus ST; Langemeijer S; Wells R; Gonzalez-Fernandez FA; Gaya A; Lee JW; Gutierrez EO; Piatek CI; Szer J; Risitano A; Nakao S; Bachman E; Shafner L; Damokosh AI; Ortiz S; Röth A; Peffault de Latour R
Blood; 2019 Feb; 133(6):540-549. PubMed ID: 30510079
[TBL] [Abstract][Full Text] [Related]
14. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Rother RP; Rollins SA; Mojcik CF; Brodsky RA; Bell L
Nat Biotechnol; 2007 Nov; 25(11):1256-64. PubMed ID: 17989688
[TBL] [Abstract][Full Text] [Related]
15. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy.
Versino F; Fattizzo B
Int J Lab Hematol; 2024 May; 46 Suppl 1():43-54. PubMed ID: 38622956
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies.
Peffault de Latour R; Brodsky RA; Ortiz S; Risitano AM; Jang JH; Hillmen P; Kulagin AD; Kulasekararaj AG; Rottinghaus ST; Aguzzi R; Gao X; Wells RA; Szer J
Br J Haematol; 2020 Nov; 191(3):476-485. PubMed ID: 32449174
[TBL] [Abstract][Full Text] [Related]
17. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
Kulasekararaj AG; Hill A; Langemeijer S; Wells R; González Fernández FA; Gaya A; Ojeda Gutierrez E; Piatek CI; Mitchell L; Usuki K; Bosi A; Brodsky RA; Ogawa M; Yu J; Ortiz S; Röth A; Lee JW; Peffault de Latour R
Eur J Haematol; 2021 Mar; 106(3):389-397. PubMed ID: 33301613
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan).
Schols S; Nunn MA; Mackie I; Weston-Davies W; Nishimura JI; Kanakura Y; Blijlevens N; Muus P; Langemeijer S
Br J Haematol; 2020 Jan; 188(2):334-337. PubMed ID: 31840801
[No Abstract] [Full Text] [Related]
19. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey.
Dingli D; Matos JE; Lehrhaupt K; Krishnan S; Yeh M; Fishman J; Sarda SP; Baver SB
Ann Hematol; 2022 Feb; 101(2):251-263. PubMed ID: 34973099
[TBL] [Abstract][Full Text] [Related]
20. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.
Peipert JD; Kulasekararaj AG; Gaya A; Langemeijer SMC; Yount S; Gonzalez-Fernandez FA; Ojeda Gutierrez E; Martens C; Sparling A; Webster KA; Cella D; Tomazos I; Ogawa M; Piatek CI; Wells R; Sicre de Fontbrune F; Röth A; Mitchell L; Hill A; Kaiser K
PLoS One; 2020; 15(9):e0237497. PubMed ID: 32886668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]